Market Overview

UPDATE: Piper Jaffray Cuts PT to $32 on Theravance Following New Convertible Offering

Related THRX
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan
Theravance Just Lost Its Catalyst

Piper Jaffray reiterated its Overweight rating on Theravance (NASDAQ: THRX) and lowered the price target from $35.00 to $32.00.

Piper Jaffray commented, “We are reiterating our OW rating on THRX shares, but lowering our PT to $32 from $35 following a $287.5mn convertible offering. We believe current valuation assumes less than 50/50 chance of Breo getting regulatory approval by its May 12, 2013 PDUFA date and assumes additional Phase III trials are required prior to approval of Anoro (LAMA/LABA). We expect the Breo FDA panel on March 7, 2013 to pave the way for a 2013 launch and support upside to shares closer to our price target.”

Theravance closed at $21.27 on Friday.

Latest Ratings for THRX

May 2015Cowen & CompanyDowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (THRX)

Get Benzinga's Newsletters